Literature DB >> 7743130

Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.

L Tong1, S Pav, S Mui, D Lamarre, C Yoakim, P Beaulieu, P C Anderson.   

Abstract

BACKGROUND: The HIV protease is essential for the life cycle of the virus and is an important target for the development of therapeutic treatments against AIDS. The structures of HIV protease in complex with different inhibitors have helped in understanding the interactions between inhibitors and the protease and in the design and optimization of HIV protease inhibitors.
RESULTS: We report here crystal structures at up to 1.7 A resolution of the homodimeric HIV-2 protease in complex with seven inhibitors containing the hydroxyethylamine dipeptide isostere. A novel dimethylphenoxyacetyl group that is present in some of these inhibitors is inserted between residues 48' and 49' in the flap of the protease and residues 29' and 30' (where a prime indicates a residue in the second monomer), which undergo a conformational change to accommodate the phenyl ring of the inhibitor.
CONCLUSIONS: This study shows that besides the residues in the flap and residues 79-81 in the S1 substrate-binding pocket which undergo conformational changes upon inhibitor binding, residues 29 and 30 can also adapt their conformation to fit certain inhibitors. Conformational flexibility of the HIV protease plays an important role in inhibitor binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743130     DOI: 10.1016/s0969-2126(01)00133-2

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  13 in total

1.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors.

Authors:  V Zoete; O Michielin; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

2.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

3.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors:  L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  D Lamarre; G Croteau; E Wardrop; L Bourgon; D Thibeault; C Clouette; M Vaillancourt; E Cohen; C Pargellis; C Yoakim; P C Anderson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Authors:  Péter Bagossi; Tamás Sperka; Anita Fehér; János Kádas; Gábor Zahuczky; Gabriella Miklóssy; Péter Boross; József Tözsér
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.

Authors:  Mi Li; Gary S Laco; Mariusz Jaskolski; Jan Rozycki; Jerry Alexandratos; Alexander Wlodawer; Alla Gustchina
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

7.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

Authors:  H L Sham; D J Kempf; A Molla; K C Marsh; G N Kumar; C M Chen; W Kati; K Stewart; R Lal; A Hsu; D Betebenner; M Korneyeva; S Vasavanonda; E McDonald; A Saldivar; N Wideburg; X Chen; P Niu; C Park; V Jayanti; B Grabowski; G R Granneman; E Sun; A J Japour; J M Leonard; J J Plattner; D W Norbeck
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.

Authors:  Andrey Y Kovalevsky; John M Louis; Annie Aniana; Arun K Ghosh; Irene T Weber
Journal:  J Mol Biol       Date:  2008-09-20       Impact factor: 5.469

10.  Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.

Authors:  Dhoha Triki; Mario Enrique Cano Contreras; Delphine Flatters; Benoit Visseaux; Diane Descamps; Anne-Claude Camproux; Leslie Regad
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.